Wandeler to leave MorphoSys
Plus: Rubius, AstraZeneca, Landos, Nyxoah, Progenity and more
Roland Wandeler is leaving MorphoSys AG (Xetra:MOR; NASDAQ:MOR) as COO effective Dec. 31 to pursue a new opportunity. Wandeler has helped strengthen the German biotech’s U.S. operations and lead the launch of Monjuvi tafasitamab-cxix, which FDA granted accelerated approval to treat relapsed or refractory diffuse large B cell lymphoma in July 2020. The commercial organization led by U.S. General Manager Joe Horvat will now report directly to CEO Jean-Paul Kress.
Christina Coughlin will step down as CMO at Rubius Therapeutics Inc. (NASDAQ:RUBY) to become CEO at another company. The company promoted Laurence “Larry” Turka to CSO and head of research and translational medicine. Rubius is developing off-the-shelf allogenic cell therapies for cancer and autoimmune diseases. ...